Patents by Inventor David Bryant Batt

David Bryant Batt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY DRUG CONJUGATES
    Publication number: 20190345250
    Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: December 19, 2018
    Publication date: November 14, 2019
    Applicant: NOVARTIS AG
    Inventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Matthew John Meyer, Konstanin Petropoulos, Engin Toksoz
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20170106095
    Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: October 11, 2016
    Publication date: April 20, 2017
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20170008964
    Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: July 7, 2016
    Publication date: January 12, 2017
    Applicant: Novartis AG
    Inventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen HU, David Jenkins, Matthew John Meyer, Konstantin Petropoulos, Engin Toksoz
  • Antibody drug conjugates
    Patent number: 9498532
    Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 22, 2016
    Assignee: Novartis AG
    Inventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20140308201
    Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 16, 2014
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20140301946
    Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 9, 2014
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • Organic Compounds
    Publication number: 20090069360
    Abstract: The present invention relates to the discovery that certain compounds inhibit, regulate and/or modulate tyrosine and serine/threonine kinase and kinase-like proteins, such as RAF kinase, a serine/threonine kinase that functions in the MAP kinase signaling pathway, and is concerned with compositions which contain these compounds, and methods of using them to treat tyrosine and serine/threonine kinase and kinase-like dependent diseases, such as angiogenesis, cancer and cardiac hypertrophy.
    Type: Application
    Filed: March 14, 2007
    Publication date: March 12, 2009
    Inventors: David Bryant Batt, Rene Beerli, Guido Bold, Giorgio Caravatti, Timothy Michael Ramsey